Market Overview

US Stock Futures Edge Lower Ahead Of Jobless Claims, Wholesale Inventories Data

Share:
US Stock Futures Edge Lower Ahead Of Jobless Claims, Wholesale Inventories Data
Related PRGO
Why Perrigo Is Divesting Rights To The Best Multiple Sclerosis Drug
7 Takeaways From Perrigo's Preliminary Q4 Results
Jerome Dodson And The Parnassus Funds: Why Are They So Successful? It's Simple (Seeking Alpha)
Related
18 Biggest Mid-Day Gainers For Monday
18 Stocks Moving In Monday's Pre-Market Session

Pre-open movers

US stock futures traded lower in early pre-market trade. Data on weekly jobless claims will be released at 8:30 a.m. ET, while wholesale inventories data for February will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average tumbled 22.50 points to 17,806.50, while the Standard & Poor's 500 index futures fell 3.55 points to 2,072.45. Futures for the Nasdaq 100 index slipped 7.05 points to 4,367.70.

A Peek Into Global Markets

European markets were higher today, with the Spanish Ibex Index rising 0.36%, STOXX Europe 600 Index surging 0.62% and German DAX 30 index gaining 0.52%. French CAC 40 Index jumped 0.88% and London's FTSE 100 Index rose 0.68%.

In Asian markets, Japan's Nikkei Stock Average rose 0.75%, China's Shanghai Composite Index slipped 0.93%, Hong Kong's Hang Seng Index climbed 2.70% and India's BSE Sensex gained 0.67%.

Broker Recommendation
Analysts at William Blair downgraded Perrigo Company plc (NYSE: PRGO) from Outperform to Market Perform.

Perrigo shares rose 3.58% to $201.99 in pre-market trading.

Breaking news

  • BioLife Solutions (NASDAQ: BLFS) today announced that Cardio3 BioSciences, a leader in engineered cell therapy with clinical programs initially targeting indications in cardiovascular disease and oncology, has embedded the Company's clinical grade CryoStor cryopreservation freeze media in its ongoing Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) phase III clinical trial in Europe and Israel and the pending CHART-2 phase III clinical trial to be conducted in the United States. To read the full news, click here.
  • IBA and Toshiba Corporation (OTC: TOSBF) today announced the signing of a global collaboration to expand access to advanced particle therapy worldwide. Toshiba Medical Systems Corporation will become the distributor in Japan for Proteus┬«ONE, IBA's compact single-room proton therapy solution, and IBA will become the agent for Toshiba's Carbon Therapy Solutions outside Japan. To read the full news, click here.
  • Infinera (NASDAQ: INFN) announced its offer to acquire Transmode, a leader in metro packet-optical networking through a recommended public offer to the shareholders of Transmode). To read the full news, click here.
  • DBV Technologies (NASDAQ: DBVT) announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Viaskin Peanut for children. To read the full news, click here.

Posted-In: US Stock Futures William BlairNews Eurozone Futures Global Pre-Market Outlook Markets

 

Related Articles (BLFS + DBVT)

View Comments and Join the Discussion!